Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-Current Assets: 2019-2025

Historic Non-Current Assets for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $111.6 million.

  • 4D Molecular Therapeutics' Non-Current Assets rose 19.66% to $111.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.6 million, marking a year-over-year increase of 19.66%. This contributed to the annual value of $125.5 million for FY2024, which is 189.71% up from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' Non-Current Assets stood at $111.6 million, which was down 34.48% from $170.3 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Non-Current Assets' 5-year high stood at $183.2 million during Q1 2025, with a 5-year trough of $5.6 million in Q1 2021.
  • In the last 3 years, 4D Molecular Therapeutics' Non-Current Assets had a median value of $93.3 million in 2024 and averaged $90.4 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 1,612.90% in 2021, then tumbled by 57.48% in 2022.
  • 4D Molecular Therapeutics' Non-Current Assets (Quarterly) stood at $97.2 million in 2021, then tumbled by 57.48% to $41.3 million in 2022, then grew by 4.76% to $43.3 million in 2023, then skyrocketed by 189.71% to $125.5 million in 2024, then increased by 19.66% to $111.6 million in 2025.
  • Its Non-Current Assets stands at $111.6 million for Q3 2025, versus $170.3 million for Q2 2025 and $183.2 million for Q1 2025.